ABOUT THE PRODUCT
RiDYMO is Atombeat's proprietary AI-powered drug discovery platform. It integrates molecular design, high-accuracy computational modeling, and closed-loop experimental feedback to accelerate the identification and optimization of drug candidates.
The platform is designed to tackle hard-to-drug targets and provides a scalable solution for hit discovery and lead optimization.
The platform is designed to tackle hard-to-drug targets and provides a scalable solution for hit discovery and lead optimization.
Information is owner-confirmed
Last updated 2 months ago
Price range